Vertex Pharmaceuticals | VRTX - Capital Ordinário

Preço das Ações
431.23
Mudança Diária
-3.07 -0.71%
Mensal
-6.43%
Anual
-8.71%
Q2 Previsão
425.50




Capital Ordinário Alterar Data
AbbVie USD 1.77B 1.75B 2025-06
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Alnylam Pharmaceuticals USD 132.38M 585K 2025-12
Amgen USD 539M 1000K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Gilead Sciences USD 1.24B 1000K 2025-12
Incyte USD 198.46M 2.33M 2025-12
Insmed USD 214.26M 1.67M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
J&J USD 2.41B 584K 2025-09
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.69B 1000K 2025-09
PTC Therapeutics USD 81.47M 1.54M 2025-12
Puma Biotechnology USD 5K 0 2024-06
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 104.96M 196K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
United Therapeutics USD 43.64M 740K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12